COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil

Detalhes bibliográficos
Autor(a) principal: Moraes, Rafael R
Data de Publicação: 2022
Outros Autores: Correa, Marcos B, Martins-Filho, Paulo R, Lima, Giana S, Demarco, Flavio F
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Journal of applied oral science (Online)
Texto Completo: https://www.revistas.usp.br/jaos/article/view/203246
Resumo: Objective: This cross-sectional study with dentists in Brazil assessed the COVID-19 incidence and severity, its vaccination status, and the level of confidence in vaccines in May 2021 (COVID-19 second wave). The medications used to prevent or treat COVID-19, including controversial substances (vitamin D, ivermectin, zinc, and chloroquine), were analyzed. Methodology: Dentists were recruited by email and responded to a pretested questionnaire until May 31, 2021. Bivariate and multivariate regression analyses were performed (α=0.05). Prevalence ratios were calculated for the association between professional characteristics and two outcomes: SARS-CoV-2 infection and use of controversial substances. Results: In total, 1,907 responses were received (return rate of 21.2%). One third of dentists reported intermediate levels of confidence in the safety and efficacy of COVID-19 vaccines, but 96% had received at least one vaccine dose, mainly CoronaVac. The effect of the pandemic on dental practice was classified as lower/much lower, in comparison with the first wave, by 46% of participants. Moreover, 27% of dentists had already tested positive for SARS-CoV-2 and about 50% had relatives or friends who had been hospitalized or died from COVID-19. At least one medication was used by 59% of participants and 43% used two or more substances. Vitamin D (41%), ivermectin (35%), and zinc (29%) were the most frequent substances. More experienced dentists (≥21 years of professional experience) were 42% more likely to use controversial substances than less experienced dentists. The prevalence of use of controversial substances was 30% higher among dentists with residency or advanced training, such as postgraduate degrees, in comparison with participants holding MSc or PhD degrees. Participants with low confidence in vaccines were 2.1 times more likely to use controversial substances than participants with a very high confidence. Conclusion: The results of this study show the high severity of the COVID-19 pandemic in Brazil and raised questions about the use of scientific evidence by dentists in their decision to use controversial substances.
id USP-17_fbea5184173970808ea23adc666b9549
oai_identifier_str oai:revistas.usp.br:article/203246
network_acronym_str USP-17
network_name_str Journal of applied oral science (Online)
repository_id_str
spelling COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in BrazilCOVID-19 vaccinesVitamin DZincIvermectinChloroquineObjective: This cross-sectional study with dentists in Brazil assessed the COVID-19 incidence and severity, its vaccination status, and the level of confidence in vaccines in May 2021 (COVID-19 second wave). The medications used to prevent or treat COVID-19, including controversial substances (vitamin D, ivermectin, zinc, and chloroquine), were analyzed. Methodology: Dentists were recruited by email and responded to a pretested questionnaire until May 31, 2021. Bivariate and multivariate regression analyses were performed (α=0.05). Prevalence ratios were calculated for the association between professional characteristics and two outcomes: SARS-CoV-2 infection and use of controversial substances. Results: In total, 1,907 responses were received (return rate of 21.2%). One third of dentists reported intermediate levels of confidence in the safety and efficacy of COVID-19 vaccines, but 96% had received at least one vaccine dose, mainly CoronaVac. The effect of the pandemic on dental practice was classified as lower/much lower, in comparison with the first wave, by 46% of participants. Moreover, 27% of dentists had already tested positive for SARS-CoV-2 and about 50% had relatives or friends who had been hospitalized or died from COVID-19. At least one medication was used by 59% of participants and 43% used two or more substances. Vitamin D (41%), ivermectin (35%), and zinc (29%) were the most frequent substances. More experienced dentists (≥21 years of professional experience) were 42% more likely to use controversial substances than less experienced dentists. The prevalence of use of controversial substances was 30% higher among dentists with residency or advanced training, such as postgraduate degrees, in comparison with participants holding MSc or PhD degrees. Participants with low confidence in vaccines were 2.1 times more likely to use controversial substances than participants with a very high confidence. Conclusion: The results of this study show the high severity of the COVID-19 pandemic in Brazil and raised questions about the use of scientific evidence by dentists in their decision to use controversial substances.Universidade de São Paulo. Faculdade de Odontologia de Bauru2022-10-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://www.revistas.usp.br/jaos/article/view/20324610.1590/1678-7757-2022-0016 Journal of Applied Oral Science; Vol. 30 (2022); e20220016Journal of Applied Oral Science; Vol. 30 (2022); e20220016Journal of Applied Oral Science; v. 30 (2022); e202200161678-77651678-7757reponame:Journal of applied oral science (Online)instname:Universidade de São Paulo (USP)instacron:USPenghttps://www.revistas.usp.br/jaos/article/view/203246/187223Copyright (c) 2022 Journal of Applied Oral Sciencehttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMoraes, Rafael RCorrea, Marcos BMartins-Filho, Paulo RLima, Giana SDemarco, Flavio F2022-10-05T13:34:40Zoai:revistas.usp.br:article/203246Revistahttp://www.scielo.br/jaosPUBhttps://www.revistas.usp.br/jaos/oai||jaos@usp.br1678-77651678-7757opendoar:2022-10-05T13:34:40Journal of applied oral science (Online) - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
title COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
spellingShingle COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
Moraes, Rafael R
COVID-19 vaccines
Vitamin D
Zinc
Ivermectin
Chloroquine
title_short COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
title_full COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
title_fullStr COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
title_full_unstemmed COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
title_sort COVID-19 incidence, severity, medication use, and vaccination among dentists: survey during the second wave in Brazil
author Moraes, Rafael R
author_facet Moraes, Rafael R
Correa, Marcos B
Martins-Filho, Paulo R
Lima, Giana S
Demarco, Flavio F
author_role author
author2 Correa, Marcos B
Martins-Filho, Paulo R
Lima, Giana S
Demarco, Flavio F
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Moraes, Rafael R
Correa, Marcos B
Martins-Filho, Paulo R
Lima, Giana S
Demarco, Flavio F
dc.subject.por.fl_str_mv COVID-19 vaccines
Vitamin D
Zinc
Ivermectin
Chloroquine
topic COVID-19 vaccines
Vitamin D
Zinc
Ivermectin
Chloroquine
description Objective: This cross-sectional study with dentists in Brazil assessed the COVID-19 incidence and severity, its vaccination status, and the level of confidence in vaccines in May 2021 (COVID-19 second wave). The medications used to prevent or treat COVID-19, including controversial substances (vitamin D, ivermectin, zinc, and chloroquine), were analyzed. Methodology: Dentists were recruited by email and responded to a pretested questionnaire until May 31, 2021. Bivariate and multivariate regression analyses were performed (α=0.05). Prevalence ratios were calculated for the association between professional characteristics and two outcomes: SARS-CoV-2 infection and use of controversial substances. Results: In total, 1,907 responses were received (return rate of 21.2%). One third of dentists reported intermediate levels of confidence in the safety and efficacy of COVID-19 vaccines, but 96% had received at least one vaccine dose, mainly CoronaVac. The effect of the pandemic on dental practice was classified as lower/much lower, in comparison with the first wave, by 46% of participants. Moreover, 27% of dentists had already tested positive for SARS-CoV-2 and about 50% had relatives or friends who had been hospitalized or died from COVID-19. At least one medication was used by 59% of participants and 43% used two or more substances. Vitamin D (41%), ivermectin (35%), and zinc (29%) were the most frequent substances. More experienced dentists (≥21 years of professional experience) were 42% more likely to use controversial substances than less experienced dentists. The prevalence of use of controversial substances was 30% higher among dentists with residency or advanced training, such as postgraduate degrees, in comparison with participants holding MSc or PhD degrees. Participants with low confidence in vaccines were 2.1 times more likely to use controversial substances than participants with a very high confidence. Conclusion: The results of this study show the high severity of the COVID-19 pandemic in Brazil and raised questions about the use of scientific evidence by dentists in their decision to use controversial substances.
publishDate 2022
dc.date.none.fl_str_mv 2022-10-05
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.revistas.usp.br/jaos/article/view/203246
10.1590/1678-7757-2022-0016
url https://www.revistas.usp.br/jaos/article/view/203246
identifier_str_mv 10.1590/1678-7757-2022-0016
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://www.revistas.usp.br/jaos/article/view/203246/187223
dc.rights.driver.fl_str_mv Copyright (c) 2022 Journal of Applied Oral Science
http://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Copyright (c) 2022 Journal of Applied Oral Science
http://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Odontologia de Bauru
publisher.none.fl_str_mv Universidade de São Paulo. Faculdade de Odontologia de Bauru
dc.source.none.fl_str_mv Journal of Applied Oral Science; Vol. 30 (2022); e20220016
Journal of Applied Oral Science; Vol. 30 (2022); e20220016
Journal of Applied Oral Science; v. 30 (2022); e20220016
1678-7765
1678-7757
reponame:Journal of applied oral science (Online)
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Journal of applied oral science (Online)
collection Journal of applied oral science (Online)
repository.name.fl_str_mv Journal of applied oral science (Online) - Universidade de São Paulo (USP)
repository.mail.fl_str_mv ||jaos@usp.br
_version_ 1800221683289686016